4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
$15.32 -0.4 (-2.5445%)
Analysed 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) News Sources
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
06-08-2026
yahoo.com
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
13-08-2026
yahoo.com
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
13-08-2026
yahoo.com
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
27-05-2026
yahoo.com
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
23-06-2026
yahoo.com
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
29-06-2026
yahoo.com
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
13-08-2026
yahoo.com
4DMT Announces New Employment Inducement Grants
14-08-2026
yahoo.com
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
17-08-2026
stocktwits.com
4DMT to Participate in Upcoming Investor Conferences
25-08-2026
yahoo.com
What is the current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is $15.32.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) absolute price change since previous trading day?
The absolute price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is $-0.4.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) percentage price change since previous trading day?
The percentage price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is -2.5445%.
What is the most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is .
SEC-8K** Filing Available For 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.